Web Results
Content Results
  • Feline hepatic lipidosis

    serch.it?q=Feline-hepatic-lipidosis

    Cat with noticeable jaundice from late-stage hepatic lipidosis. Note the ears and eye-membraneFeline hepatic lipidosis, also known as feline fatty liver syndrome, is one of the most common forms of liver disease of cats. The disease officially has no known cause, though obesity is known to increase the risk. The disease begins when the cat stops eating from a loss of appetite, forcing the liver to convert body fat into usable energy. If this process continues for too long, fat builds up in the cells of the liver, and the disease has officially onset. Prognosis varies depending on the stage of the disease, with both a high recovery and mortality rate at different stages. The disease is reversible through intense feeding. Treatment may involve the insertion of a temporary feeding tube to ensure adequate caloric intake for cats that have stopped eating as a result of this disease.

  • Weight loss

    serch.it?q=Weight-loss

    Weight loss, in the context of medicine, health, or physical fitness, refers to a reduction of the total body mass, due to a mean loss of fluid, body fat or adipose tissue or lean mass, namely bone mineral deposits, muscle, tendon, and other connective tissue. Weight loss can either occur unintentionally due to malnourishment or an underlying disease or arise from a conscious effort to improve an actual or perceived overweight or obese state. "Unexplained" weight loss that is not caused by reduction in calorific intake or exercise is called cachexia and may be a symptom of a serious medical condition. Intentional weight loss is commonly referred to as slimming.

  • Non-alcoholic fatty liver disease

    serch.it?q=Non-alcoholic-fatty-liver-disease

    Non-alcoholic fatty liver disease (NAFLD) is when excess fat builds up in the liver due to causes other than alcohol use. There are two types: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver usually does not progress to liver damage or NASH. NASH includes both a fatty liver and liver inflammation. It may lead to complications such as cirrhosis, liver cancer, liver failure, or cardiovascular disease. Risk factors include diabetes, obesity, a diet high in fructose and older age. NAFLD is a type of fatty liver disease together with alcoholic liver disease. NAFLD is related to insulin resistance and metabolic syndrome. It can be diagnosed by a liver biopsy. Treatment is generally with weight loss by dietary changes and exercise. There is tentative evidence for pioglitazone and vitamin E. Those with NASH have a 2.6% risk of dying per year. NAFLD is the most common liver disorder in developed countries, affecting 75 to 100 millions Americans in 2017. Up to 80% of obese and up to 20% normal-weight people might develop it. It is estimated that 24% of the worldwide population is affected in 2017. NAFLD is the leading cause of chronic liver disease as of 2017. About 12 to 25% of people in the United States have NAFLD, while NASH affects between 2 and 12%. The annual economic burden was estimated at US$103 billion in the US in 2016.

Map Box 1